Happi Staff07.20.20
According to Sytheon, there are certain novel esters of isosorbide that have been found to address defects or imbalances in keratinocyte differentiation, repair skin barrier building and defense, and improve overall stratum corneum development, structure and architecture. Specifically, Sytheon says that certain esters of isosorbide are capable of modifying, recalibrating and/or regulating the expression of genes, genetic networks and cellular pathways in mammalian skin for improving and/or repairing the epidermis and its function as well as in addressing, combating, mitigating and/or preventing the manifestation of disease conditions associated with certain diseases and defects or imbalances in the skin.
Having secured this patent, Sytheon says it is now committed to enter, through its sister company Symbionyx Phamaceuticals Inc., the dermatological market for treating diseases caused by autoimmune imbalances.
Having secured this patent, Sytheon says it is now committed to enter, through its sister company Symbionyx Phamaceuticals Inc., the dermatological market for treating diseases caused by autoimmune imbalances.
